Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
81 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Rhino-Conjunctivitis - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhino-Conjunctivitis - Pipeline Review, H2 2016, provides an overview of the Rhino-Conjunctivitis (Ophthalmology) pipeline landscape. Rhinitis is characterized by one or several of the following symptoms: nasal congestion, runny nose, post-nasal drip, sneezing, red eyes (conjunctivitis), and itching of the nose or eyes. It may be allergic or non-allergic. It is important to enact environmental control measures to avoid the allergens that are causing the problem. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rhino-Conjunctivitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rhino-Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Rhino-Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Rhino-Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 3, 5, 8, 3 and 1 respectively. Rhino-Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Rhino-Conjunctivitis (Ophthalmology). - The pipeline guide reviews pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Rhino-Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Rhino-Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Rhino-Conjunctivitis (Ophthalmology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Rhino-Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Rhino-Conjunctivitis Overview 8 Therapeutics Development 9 Pipeline Products for Rhino-Conjunctivitis - Overview 9 Rhino-Conjunctivitis - Therapeutics under Development by Companies 10 Rhino-Conjunctivitis - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Rhino-Conjunctivitis - Products under Development by Companies 14 Rhino-Conjunctivitis - Companies Involved in Therapeutics Development 15 ALK-Abello A/S 15 Allergy Therapeutics Plc 16 ASIT Biotech SA 17 Astellas Pharma Inc 18 Bial - Portela & Ca SA 19 Circassia Pharmaceuticals Plc 20 Griffin Discoveries BV 21 HAL Allergy BV 22 Laboratorios LETI SL 23 Oxagen Ltd 24 Roxall Medizin GmbH 25 Stallergenes Greer plc 26 Rhino-Conjunctivitis - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Combination Products 28 Assessment by Target 29 Assessment by Mechanism of Action 31 Assessment by Route of Administration 33 Assessment by Molecule Type 35 Drug Profiles 37 Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Allergen for Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Allergen for Allergic Rhino-Conjunctivitis - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Allergovac - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 ASP-4070 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 clustoid wiesenlieschgras - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 gp-ASIT - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 hdm-ASIT - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 OC-2417 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Pollinex Quattro Grass - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Timapiprant - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 Vaccine for House Dust Mite Induced Allergic Rhinoconjunctivitis - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 Rhino-Conjunctivitis - Dormant Projects 70 Rhino-Conjunctivitis - Discontinued Products 72 Rhino-Conjunctivitis - Product Development Milestones 73 Featured News & Press Releases 73 Jun 13, 2014: Circassia Announces Results from House Dust Mite Allergy Treatment Phase IIb Two-Year Follow-up Study 73 Jun 09, 2014: ALK presents Phase III data on house dust mite SLIT-tablet at EAACI Annual Congress in Copenhagen 74 May 18, 2014: BioTech Tools will be present at the EAACI congress 75 Mar 10, 2014: GREER Investigational Sublingual Allergy Immunotherapy Liquid (SAIL) for Short Ragweed Allergies Phase III Data Published in Journal of Allergy and Clinical Immunology 76 Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics 77 Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites 78 Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA 78 Oct 31, 2011: HAL Allergy Includes First Patient In Phase II PURETHAL Mites Study 79 Appendix 80 Methodology 80 Coverage 80 Secondary Research 80 Primary Research 80 Expert Panel Validation 80 Contact Us 80 Disclaimer 81
List of Tables
Number of Products under Development for Rhino-Conjunctivitis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Rhino-Conjunctivitis - Pipeline by ALK-Abello A/S, H2 2016 15 Rhino-Conjunctivitis - Pipeline by Allergy Therapeutics Plc, H2 2016 16 Rhino-Conjunctivitis - Pipeline by ASIT Biotech SA, H2 2016 17 Rhino-Conjunctivitis - Pipeline by Astellas Pharma Inc, H2 2016 18 Rhino-Conjunctivitis - Pipeline by Bial - Portela & Ca SA, H2 2016 19 Rhino-Conjunctivitis - Pipeline by Circassia Pharmaceuticals Plc, H2 2016 20 Rhino-Conjunctivitis - Pipeline by Griffin Discoveries BV, H2 2016 21 Rhino-Conjunctivitis - Pipeline by HAL Allergy BV, H2 2016 22 Rhino-Conjunctivitis - Pipeline by Laboratorios LETI SL, H2 2016 23 Rhino-Conjunctivitis - Pipeline by Oxagen Ltd, H2 2016 24 Rhino-Conjunctivitis - Pipeline by Roxall Medizin GmbH, H2 2016 25 Rhino-Conjunctivitis - Pipeline by Stallergenes Greer plc, H2 2016 26 Assessment by Monotherapy Products, H2 2016 27 Assessment by Combination Products, H2 2016 28 Number of Products by Stage and Target, H2 2016 30 Number of Products by Stage and Mechanism of Action, H2 2016 32 Number of Products by Stage and Route of Administration, H2 2016 34 Number of Products by Stage and Molecule Type, H2 2016 36 Rhino-Conjunctivitis - Dormant Projects, H2 2016 70 Rhino-Conjunctivitis - Dormant Projects (Contd..1), H2 2016 71 Rhino-Conjunctivitis - Discontinued Products, H2 2016 72
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
